在多发性骨髓瘤中,Belantamab 不会诱导B细胞成熟抗原损失或全身免疫功能障碍
Hanny Musa1, Michał Mielnik2, Suzanne Trudel3
1GSK, Baar Onyx. hanny.m.musa@gsk.com.
Haematologica
|August 28, 2025
概括
针对B细胞成熟抗原 (BCMA) 的抗体- 药物结合物Belantamab mafodotin在多发性骨髓瘤中具有早期使用的潜力. 它不会对T细胞适应性或BCMA结合产生负面影响,支持其在其他BCMA疗法之前的测序.
科学领域:
- 癌症学
- 免疫疗法
- 药理学
背景情况:
- B细胞成熟抗原 (BCMA) 是多发性骨髓瘤治疗的目标,包括CAR-T细胞,双特异性抗体 (bsAbs) 和抗体与药物联合体 (ADC).
- T细胞耗尽和向抗原损失可能会限制目前的BCMA向治疗的有效性.
- 针对BCMA治疗的最佳测序对于改善多发性骨髓瘤的长期结果至关重要.
研究的目的:
- 在多发性骨髓瘤患者中评估贝兰塔马布对BCMA水平,结合亲和力和免疫细胞适应性的影响.
- 为了确定贝兰塔马布马福多丁在其他BCMA向疗法之前的测序潜力.
主要方法:
- 分析涉及贝兰他马夫多丁 (单疗法和联合疗法) 的临床数据.
- 使用电化学发光测量可溶性BCMA (sBCMA) 度和贝兰他巴与sBCMA的结合.
- 评估T细胞和自然杀手细胞数量以及功能性,耗尽性和增殖性标志物的表达.
主要成果:
- 在最佳反应情况下,可溶性BCMA水平下降,但在进展时恢复到基线.
- 贝兰塔马布对BCMA的结合没有受到影响,这表明它对标表位没有影响.
- 没有观察到T细胞/ NK细胞数量或疲劳,共刺激,增殖或抗瘤活性标志物的显著变化.
结论:
- 贝兰塔马布治疗没有影响BCMA结合或T细胞/NK细胞适应性.
- 这些发现支持在治疗多发性骨髓瘤的早期阶段使用贝兰塔马布.
- 需要进一步的证实性研究来确定最佳的测序策略.
更多相关视频
10:35Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
8.4K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.3K
相关概念视频
Cell-mediated Immune Responses
Overview
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Special Features of Adaptive Immunity
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Cells of the Adaptive Immune Response
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
